| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
Amrinone (or inamrinone) is a type 3 pyridine phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure. |
| Indication |
Used in the treatment of congestive heart failure. |
| Pharmacology |
Amrinone is a positive inotropic cardiotonic with vasodilator properties, phosphodiesterase inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
Hepatic. |
| Half Life |
5 to 8 hours |
| Protein Binding |
10 to 49% |
| Elimination |
The primary route of excretion in man is via the urine as both inamrinone and several metabolites (N-glycolyl, N-acetate, O-glucuronide and N-glucuronide). |
| Distribution |
* 1.2 L/kg [normal volunteers] |
| External Links |
|